HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer

The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer. The main questions it aims to answer are: Can HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of HDAC inhibitors and neoadjuvant immunochemotherapy achieve a better long-term prognosis than neoadj

Trial Details

NCT ID
NCT06709885
Phase
PHASE2
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Chidamide + Tislelizumab + chemotherapy (CapeOX )
  • CapeOX
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Signed written informed consent to voluntarily join this study
  • Patients with colon cancer who are assessed by abdominal contrast-enhanced CT/abdominopelvic MRI as high-risk T3 (tumor destroys muscle wall and ex…
  • Adenocarcinoma of the colon confirmed by histopathological examination.
  • At least 18 years old, male or female.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →